E-ISSN 2602-3164
ejmi. 2019; 3(4): 322-326 | DOI: 10.14744/ejmi.2019.70738

Assessment of Efficacy, Reliability, Side Effects and Patient Compliance of Entecavir in Turkish Patients with Nukleos(t)ide Analogues Naive Chronic Hepatitis B

Mustafa Karaagac1, Nevzat Aksoy1, Kemal Kutoglu1, Nurten Arican1, Semih Kalyon1, Necati Yenice1
1Department of Internal Medicine, Health Sciences University, Okmeydani Training and Research Hospital, Istanbul, Turkey

Objectives: This study aimed to assess the entecavir (ENT) in Turkish patients with nukleos(t)ide analogues (NA) naive chronic hepatitis B (CHB). Methods: The data in this study were collected retrospectively. The rates of compliance, biological, virological, and serological responses, and drug resistance and the frequency of ENT-related side effects were determined. Results: A total of 40 patients were enrolled in this study. The rates of virological response, biochemical response in HBeAg (-) patients were 100% and 96.6%, respectively. There was no HBsAg loss in HBeAg (-) patients. The rates of virological response, biochemical response, serological response, and HBsAg loss in HBeAg (+) patients were 100%, 90%, 70%, and 10% respectively. The rates of virological response and biochemical response in both HBeAg (-) and (+) patients were 100% and 95%, respectively. Complete response was detected in only one of 40 patients (2.5%) at the 96th week of treatment. The most ENT-related side effects were fatigue. Only two patients had mild renal impairment, whereas moderate or severe renal impairment was not detected. Conclusion: The treatment of ENT can be safely used as an effective first-line drug in adult Turkish patients with NAnaive CHB. Patients should be followed up more closely in terms of renal function during treatment. Keywords: chronic hepatitis B, entecavir, efficacy, naive


Cite This Article

Karaagac M, Aksoy N, Kutoglu K, Arican N, Kalyon S, Yenice N. Assessment of Efficacy, Reliability, Side Effects and Patient Compliance of Entecavir in Turkish Patients with Nukleos(t)ide Analogues Naive Chronic Hepatitis B. ejmi. 2019; 3(4): 322-326

Corresponding Author: Karaagac M.

Full Text PDF